… efficacy with higher doses, 12 ,15 clinicians should remain cognizant of the disadvantages of
higher-activity RAI, including patient … -activity RAI to evaluate their efficacy concerning rates …

… Radioiodine ( 131 I) remnant ablation (RRA) has become a key step in the postoperative
treatment of differentiated thyroid cancer (… the feasibility of radioiodine uptake and thyroglobulin (…

… effectiveness of RAI remnant ablation for thyroid cancer-related outcomes of PTMC patients.
… including 8724 patients, assessing the effectiveness of RAI remnant ablation therapy for …

… RAI remnant ablation consists of the destruction of the remnant thyroid tissue with the …
adverse effects of radioiodine therapy for differentiated thyroid carcinoma—a systematic review. …

… efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with
differentiated thyroid cancer … remnant ablation in patients with differentiated thyroid cancer. …

Background The clinical outcomes of delayed radioiodine remnant ablation (RRA) therapy
in patients with low-risk papillary thyroid carcinoma (PTC) are unclear. We aimed to evaluate …

… trials specifically designed to assess the efficacy and optimal administered activity of 131 I …
low-dose radioactive iodine for treatment of patients with low-risk differentiated thyroid cancer. …

… Overall, 4000 patients with papillary thyroid cancer, differentiated thyroid … mCi) in order to
maximize therapeutic activity and radioiodine effectiveness in metastatic differentiated thyroid …

… efficacy of 131 I remnant ablation.” However, in their 2019 provocative editorial entitled “Guidelines
are not gospels,” Daniels and Kopp, 6 as they looked toward the future, stated, “We …

… However, the efficacy of these … RAI remnant ablation was performed in indicated patients
4–6 weeks after the initial operation. At our institution, high-dose (>100 mCi) remnant ablation is …